Biography and Research Information
OverviewAI-generated summary
R. Scicali's research investigates the role of proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors in managing familial hypercholesterolemia. Their work has explored how these inhibitors affect platelet net release, a factor contributing to thrombosis in individuals with this genetic condition. Additionally, Scicali has examined the impact of PCSK9 inhibition on serum lipoprotein functions in patients diagnosed with homozygous familial hypercholesterolemia, including cases with delayed diagnosis. This research contributes to understanding the broader implications of PCSK9 inhibition beyond cholesterol reduction, focusing on its potential to mitigate thrombotic risks and improve lipid profiles in specific patient populations.
Metrics
- Publications: 3
Selected Publications
-
OC 10.4 Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Nets Release Driver Thrombosis in Familial Hypercholesterolemia (2023)
Collaboration Network
Top Collaborators
A.B. Cefalù
University of Palermo (IT)
2 shared publications
- Inhibition of PCSK9 affects serum lipoprotein functions in patients with familial hypercholesterolemia
- Management of a patient with delayed diagnosis of homozygous familial hypercholesterolaemia
D. Noto
University of Palermo (IT)
2 shared publications
- Inhibition of PCSK9 affects serum lipoprotein functions in patients with familial hypercholesterolemia
- Management of a patient with delayed diagnosis of homozygous familial hypercholesterolaemia
S. Piro
Ospedale Garibaldi (IT)
2 shared publications
- Inhibition of PCSK9 affects serum lipoprotein functions in patients with familial hypercholesterolemia
- Management of a patient with delayed diagnosis of homozygous familial hypercholesterolaemia
A. Di Pino
Ospedale Garibaldi (IT)
2 shared publications
- Inhibition of PCSK9 affects serum lipoprotein functions in patients with familial hypercholesterolemia
- Management of a patient with delayed diagnosis of homozygous familial hypercholesterolaemia
M. Averna
University of Palermo (IT)
2 shared publications
- Inhibition of PCSK9 affects serum lipoprotein functions in patients with familial hypercholesterolemia
- Management of a patient with delayed diagnosis of homozygous familial hypercholesterolaemia
F. Purrello
University of North Carolina at Chapel Hill (US)
2 shared publications
- Inhibition of PCSK9 affects serum lipoprotein functions in patients with familial hypercholesterolemia
- OC 10.4 Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Nets Release Driver Thrombosis in Familial Hypercholesterolemia
Marcella Palumbo
University of Parma (IT)
1 shared publication
- Inhibition of PCSK9 affects serum lipoprotein functions in patients with familial hypercholesterolemia
M.P. Adorni
University of Parma (IT)
1 shared publication
- Inhibition of PCSK9 affects serum lipoprotein functions in patients with familial hypercholesterolemia
F. Zimetti
University of Parma (IT)
1 shared publication
- Inhibition of PCSK9 affects serum lipoprotein functions in patients with familial hypercholesterolemia
C. Pavanello
University of Milan (IT)
1 shared publication
- Inhibition of PCSK9 affects serum lipoprotein functions in patients with familial hypercholesterolemia
A. Giammanco
University of Palermo (IT)
1 shared publication
- Inhibition of PCSK9 affects serum lipoprotein functions in patients with familial hypercholesterolemia
L. Calabresi
University of Milan (IT)
1 shared publication
- Inhibition of PCSK9 affects serum lipoprotein functions in patients with familial hypercholesterolemia
F. Bernini
University of Parma (IT)
1 shared publication
- Inhibition of PCSK9 affects serum lipoprotein functions in patients with familial hypercholesterolemia
Alessandra Giammanco
University of Palermo (IT)
1 shared publication
- Management of a patient with delayed diagnosis of homozygous familial hypercholesterolaemia
C. Scrimali
University of Palermo (IT)
1 shared publication
- Management of a patient with delayed diagnosis of homozygous familial hypercholesterolaemia
Similar Researchers
Based on overlapping research topics
John Imig
University of Arkansas for Medical Sciences
Cardiovascular Function and Risk Factors
Metabolism and Genetic Disorders
Pharmacological Effects and Toxicity Studies
RANEY L. HALEY
National Center for Toxicological Research
Cardiovascular Function and Risk Factors
Metabolism and Genetic Disorders
Pharmacological Effects and Toxicity Studies
Alicia Racelis
University of Arkansas at Fayetteville
Metabolism and Genetic Disorders
Pharmacological Effects and Toxicity Studies
Health and Medical Research Impacts
Kelly K. Ball
University of Arkansas for Medical Sciences
Cardiovascular Function and Risk Factors
Pharmacological Effects and Toxicity Studies
Platelet Disorders and Treatments
J.S. Guimbellot
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Pharmacological Effects and Toxicity Studies
Health and Medical Research Impacts
G AKERMAN
National Center for Toxicological Research
Metabolism and Genetic Disorders
Pharmacological Effects and Toxicity Studies
Health and Medical Research Impacts